Phase 1 trial of K0706, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): In patients with chronic myelogenous leukemia (CML) and phildelphia positive acute lymphoblastic leukemia (Ph + ALL) failing ≥ 3 prior TKI therapies: Initial safety and efficacy Meeting Abstract
| Authors: | Cortes, J. E.; Kim, D. W.; Nicolini, F. E.; Saikia, T.; Charbonnier, A.; Apperley, J. F.; Rathnam, K.; Deininger, M. W.; De Lavallade, H.; Khattry, N.; Whiteley, A.; Mauro, M. J.; Verhoef, G.; Gambacorti-Passerini, C.; Lucchesi, A.; Apte, S.; Nikki, G.; Yao, S. L.; Kothekar, M.; Sreenivasan, J.; Bimba, H. V.; Chimote, G. |
| Abstract Title: | Phase 1 trial of K0706, a novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI): In patients with chronic myelogenous leukemia (CML) and phildelphia positive acute lymphoblastic leukemia (Ph + ALL) failing ≥ 3 prior TKI therapies: Initial safety and efficacy |
| Meeting Title: | 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Language: | English |
| ACCESSION: | WOS:000577164602181 |
| DOI: | 10.1182/blood-2019-129751 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4158 -- Source: Wos |
